Supplementary Table 1 from EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia

Wei Cao,Rania H. Younis,Jiang Li,Haiyan Chen,Ronghui Xia,Li Mao,Wantao Chen,Hening Ren

DOI: https://doi.org/10.1158/1940-6207.22524497

2023-01-01

Abstract:PDF file - 76K

What problem does this paper attempt to address?

Immunohistochemical Detection of Aurora A and ERK Pathway in Oral Leukoplakia and Oral Squamous Cell Carcinoma

Yan Dong,Zhiyong Li,Mingyang Gao,Caiyun Liu,Han Liu,Zhuwen Chen,Jing Xiao

DOI: https://doi.org/10.2485/jhtb.23.71

2014-01-01

Journal of Hard Tissue Biology

Abstract:Oral squamous cell carcinoma (OSCC) is one of the most common types of human cancer in the world. Oral leukoplakia (OLK) is the most commonly diagnosed premalignant lesion in the oral cavity and it is also most associated with the development of OSCC. However, the mechanism of malignant transformation from OLK to OSCC is not completely understood. In this study, we attempted to evaluate expression of Aurora A and the main effectors in the Ras/Raf/MEK/ERK pathway in OSCC and OLK clinical tissues. Protein expression was analyzed by immunohistochemical technology in 25 tissue samples of OLK and 21 OSCC clinical tumor specimens. Upon analyzing the levels of Aurora A, phospho-MEK1/2 and phospho-ERK1/2, a remarked increase was observed in tumors compared to OLK tissues. No statistically significant difference between tumor and OLK tissues was found for pRaf-1 S259 and ERK1/2. These results suggest that the increase in Aurora A, phospho-MEK1/2 and phospho-ERK1/2 expression was closely correlated with malignant transformation of OLK. Furthermore, Aurora A, phospho-MEK1/2 and phospho-ERK1/2 might be coordinated for valuable prognostic indicators of malignant transformation of OLK. In addition, more than 50% pERK1/2 immunopositive cells appears to be a good cut off value to predict the malignant transformation of OLK.
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395233

2023-01-01

Abstract:Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation

DIVYA GANESH,AMAL DAFAR,JULIA NIKLASSON,INGRID SANDBERG,PAULO BRAZ-SILVA,DIPAK SAPKOTA,JENNY ÖHMAN,DANIEL GIGLIO,BENGT HASSÉUS

DOI: https://doi.org/10.21873/anticanres.16302

2023-03-27

Anticancer Research

Abstract:BACKGROUND/AIM: The EZH2 complex is involved in cellular proliferation and modulates the immune response in cancer. Less is known about the importance of EZH2 in precancerous lesions such as oral leukoplakia (OL). The aim of the study was to explore the association between EZH2 expression, immune activation, and cancer transformation in OL.PATIENTS AND METHODS: Analyses were retrospectively performed on nine OL cases that had undergone transformation to oral squamous cell carcinoma (OSCC; OL-ca) and nine that had not undergone transformation (OL-non). EZH2-expressing cells, CD3+ and CD8+ T cells, and CD1a+ Langerhans cells were visualized with immunohistofluorescence and counted.RESULTS: A moderate positive correlation between CD3- and EZH2-expressing and CD8- and EZH2-expressing cells in the epithelium was found (r=0.57, p=0.01; r=0.59, p=0.01). The number of EZH2-expressing cells in the epithelium of OL-ca was significantly higher compared to OL-non (p=0.0002). Cancer-free survival rates differed significantly between patients with EZH2high compared to EZH2low expression (p=0.001). EZH2high expression in OL epithelium was associated with a 13-fold higher risk for developing OSCC (HR=12.8).CONCLUSION: EZH2 expression in oral epithelium predicts OSCC transformation of OL and correlates with the level of T-cell infiltration.

oncology
Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419828

2023-01-01

Abstract:Supplementary Table S2. Patient characteristics
Abstract 1143: EZH2 Promotes Oral Squamous Cell Carcinoma Initiation and Progression Through Epigenetic Silencing of FHL1

Wei Cao,Wantao Chen

DOI: https://doi.org/10.1158/1538-7445.am2012-1143

IF: 11.2

2012-01-01

Cancer Research

Abstract:Abstract Oral squamous cell carcinoma (OSCC) is widely represented as a heterogeneous tumor with more aggressive phenotypes, but the basis for these characteristics remains unknown. In the current study, we show that up-regulation of the Polycomb complex histone methytransferase EZH2 is critical to maintain the malignant phenotypes in OSCC and associated significantly with oral squamous cell carcinoma development in patients with oral leukoplakia (OLP), which represents oral precancerous lesion as well as the worse prognosis of patients with locally advanced OSCC. Patients with OLP (n=76) and OSCC (n=124) from two independent cohort were included in this study. Immunohistochemical analyses on EZH2 in the two cohort revealed that the higher EZH2 levels were strongly associated with dysplasia (P < 0.001) and OSCC development (P < 0.0001) in patients with OLP, as well as worse overall survival (P = 0.001) and disease free survival (P = 0.002) in patients with locally advanced OSCC. Furthermore, upon EZH2 silencing by small interfering RNA (siRNA)-mediated knockdown, the proliferation, anchorage-independent growth and invasion potential of OLP cell line and OSCC cell lines were remarkably suppressed. Available publicly H3K27 modifications based on CpG array and three public microarray datasets (GEO) analyses identified human four-and-half LIM protein 1(FHL1) as a novel candidate target of EZH2 in OSCC. Further depletion of EZH2 by RNA interference (RNAi), the expression of FHL1 was notably restored in OLP and OSCC cell lines. In addition, ablation of FHL1 by RNA interference promoted significantly proliferation and invasion potential of OSCC cells. Together, our findings indicate that aberrantly elevated EZH2 promotes aggressive phenotypes of OLP and OSCC cells and plays a critical role in initiation and progression of OSCC. meanwhile, FHL1 may be a novel target of EZH2 for transcriptional repression in OSCC initiation and progression. ACKNOWLEDGMENTS: This study was supported by the National Natural Science Foundation of China (Grant No. 30973343), Projects of the Shanghai Science and Technology Committee (Grant No. 08JC1414400 and 10XD1402500) and the Shanghai Leading Academic Discipline Project (S30206). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1143. doi:1538-7445.AM2012-1143
Supplementary Table S3 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Wenju Chang,Zhou Zhang,Baoqing Jia,Kefeng Ding,Zhizhong Pan,Guoqiang Su,Wei Zhang,Tianyu Liu,Yunshi Zhong,Guodong He,Li Ren,Ye Wei,Dongdong Li,Xiaolong Cui,Jun Yang,Yixiang Shi,Marc Bissonnette,Chuan He,Wei Zhang,Jia Fan,Jianmin Xu

DOI: https://doi.org/10.1158/1078-0432.26422961.v1

2024-01-01

Abstract:Participant characteristics of 80 patients with other cancers.
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Supplemental Tables 1-4 from Notch1 Mutations Are Drivers of Oral Tumorigenesis

Evgeny Izumchenko,Kai Sun,Sian Jones,Mariana Brait,Nishant Agrawal,Wayne Koch,Christine L. McCord,David R. Riley,Samuel V. Angiuoli,Victor E. Velculescu,Wei-Wen Jiang,David Sidransky

DOI: https://doi.org/10.1158/1940-6207.22526585

2023-01-01

Abstract:Supplemental Tables 1-4. Supp. Table 1. A. List of all OSCC samples used in this study and clinical/pathological data. B. List of 22 matched tumor-normal pairs. Supp. Table 2. List of all normal samples used in this study and clinical/pathological data. Supp. Table 3. List of all oral leukoplakia samples used in this study and clinical/pathological data. Supp. Table 4. Summary of clinical characteristics for OSCC, leukoplakia and normal samples used in this study.
Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Wei Cao,Rachel de Oliveira Ribeiro,Diane Liu,Pierre Saintigny,Ronghui Xia,Yuwen Xue,Ruxian Lin,Li Mao,Hening Ren

DOI: https://doi.org/10.1371/journal.pone.0052984

IF: 3.7

2012-01-01

PLoS ONE

Abstract:Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesis. Enhancer of Zeste 2 (EZH2) is the histone methyltransferase subunit in polycomb repressive complex 2 which mediates transcriptional repression through histone methylation. EZH2 overexpression has been linked to aggressive phenotypes of certain cancers. However, the mechanism that EZH2 played in promoting malignancy in non-small cell lung cancer (NSCLC) remains unclear. In addition, the correlation of EZH2 overexpression and the prognosis of NSCLC patients in non-Asian cohort need to be determined.Methodology/Principal Findings: Up-regulation of EZH2 was found in NSCLC cells compared with normal human bronchial epithelial cells by western blot assay. Upon EZH2 knockdown using small interfering RNA (siRNA), the proliferation, anchorage-independent growth and invasion of NSCLC cells were remarkably suppressed with profound induction of G1 arrest. Furthermore, the expression of cyclin D1 was notably reduced whereas p15(INK4B), p21(Waf1/Cip1) and p27(Kip1) were increased in NSCLC cells after EZH2-siRNA delivery. To determine whether EZH2 expression contributes to disease progression in patients with NSCLC, Taqman quantitative real-time RT-PCR was used to measure the expression of EZH2 in paired tumor and normal samples. Univariate analysis revealed that patients with NSCLC whose tumors had a higher EZH2 expression had significantly inferior overall, disease-specific, and disease-free survivals compared to those whose tumors expressed lower EZH2 (P = 0.005, P = 0.001 and P = 0.003, respectively). In multivariate analysis, EZH2 expression was an independent predictor of disease-free survival (hazard ratio = 0.450, 95% CI: 0.270 to 0.750, P = 0.002).Conclusions/Significance: Our results demonstrate that EZH2 overexpression is critical for NSCLC progression. EZH2 mRNA levels may serve as a prognostic predictor for patients with NSCLC.
Up-regulation of Enhancer of Zeste Homolog 2 is Associated Positively with Cyclin D1 Overexpression and Poor Clinical Outcome in Head and Neck Squamous Cell Carcinoma.

Wei Cao,Zhien Feng,Zhibin Cui,Chenping Zhang,Zhaoyao Sun,Li Mao,Wantao Chen

DOI: https://doi.org/10.1002/cncr.26575

IF: 6.9209

2011-01-01

Cancer

Abstract:BACKGROUND: The authors previously observed that enhancer of zeste homolog 2 (EZH2) overexpression was associated significantly with the development of oral cancer. In the current study, they investigated whether EZH2 can function as a prognostic predictor for patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Expression levels of EZH2 in HNSCC cells were detected using reverse transcriptase-polymerase chain reaction (PCR) and Western blot analyses. In addition, the effects of EZH2 ablation on the proliferation and invasion of HNSCC cells were investigated through small interfering RNA (siRNA)-mediated knockdown. Real-time PCR and immunohistochemistry were used to evaluate EZH2 and cyclin D1 expression in 46 HNSCC samples, and the expression levels also were re-evaluated in 124 independent samples by immunohistochemistry. RESULTS: EZH2 expression was elevated remarkably in HNSCC specimens and cell lines. Upon EZH2 silencing, the proliferation and invasion of HNSCC cells were remarkably suppressed. EZH2 expression frequently was correlated with cyclin D1 expression (P = .034) and tumor differentiation (P = .020). In addition, both EZH2 messenger RNA levels and EZH2 protein levels were strongly associated with signs of histologic severity (P = .012 and P = .032, respectively). Univariate analysis revealed that high EZH2 expression was associated with worse overall survival (P = .001) and disease-free survival (P = .002). The combined expression of EZH2 and cyclin D1 had superior prognostic ability for patients with HNSCC than the expression of either marker alone. In multivariate analysis, EZH2 expression was identified as an independent predictor of overall and disease-free survival. CONCLUSIONS: The current results indicated that EZH2 is an independent prognostic indicator for patients with HNSCC. In addition, an analysis of the combined expression of EZH2 and cyclin D1 can serve as a more powerful prognostic predictor for patients with HNSCC. Cancer 2011. (c) 2011 American Cancer Society.
Supplementary Data from Methylation of <i>p16</i> CpG Island Associated with Malignant Progression of Oral Epithelial Dysplasia: A Prospective Cohort Study

Jie Cao,Jing Zhou,Yan Gao,Liankun Gu,Hua Meng,Hongwei Liu,Dajun Deng

DOI: https://doi.org/10.1158/1078-0432.22440057.v1

2023-01-01

Abstract:Supplementary Data from Methylation of p16 CpG Island Associated with Malignant Progression of Oral Epithelial Dysplasia: A Prospective Cohort Study
Supplementary Tables 1-2, Figure 1 from HOXA13 Promotes Cancer Cell Growth and Predicts Poor Survival of Patients with Esophageal Squamous Cell Carcinoma

Zhen-Dong Gu,Lu-Yan Shen,Hua Wang,Xiao-Mei Chen,Yong Li,Tao Ning,Ke-Neng Chen

DOI: https://doi.org/10.1158/0008-5472.22378289.v1

2023-01-01

Abstract:Supplementary Tables 1-2, Figure 1 from HOXA13 Promotes Cancer Cell Growth and Predicts Poor Survival of Patients with Esophageal Squamous Cell Carcinoma
Supplementary Tables from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth Via ADAM9–EGFR–AKT Signaling

Ronghua Liu,Jie Gu,Pei Jiang,Yijie Zheng,Xiaoming Liu,Xuechao Jiang,Enyu Huang,Shudao Xiong,Fengkai Xu,Guangwei Liu,Di Ge,Yiwei Chu

DOI: https://doi.org/10.1158/1078-0432.22460703

2023-01-01

Abstract:The file included six supplementary tables as following: Table S1.Clinicopathological Characteristics; Table S2. Differently expressed miRNAs between ECs and NMs; Table S3. Univariate and Multivariate analysis of factors associated with disease-specific survival; Table S4. A short list of functionally relevant genes significantly downredulated in 126-EC cells vs. NC-EC cells; Table S5. Primer sequences (5'-3'), Table S6. The primary antibodies for western blot and IHC.
Supplemental Figure 2 from Notch1 Mutations Are Drivers of Oral Tumorigenesis

Evgeny Izumchenko,Kai Sun,Sian Jones,Mariana Brait,Nishant Agrawal,Wayne Koch,Christine L. McCord,David R. Riley,Samuel V. Angiuoli,Victor E. Velculescu,Wei-Wen Jiang,David Sidransky

DOI: https://doi.org/10.1158/1940-6207.22526597.v1

2023-01-01

Abstract:Supplemental Figure 2. List of all NOTCH1 mutations identified in Chinese patients with oral leukoplakia.
Supplementary Tables 1-5 from 14-3-3ζ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival

Christopher L. Neal,Jun Yao,Wentao Yang,Xiaoyan Zhou,Nina T. Nguyen,Jing Lu,Christopher G. Danes,Hua Guo,Keng-Hsueh Lan,Joe Ensor,Walter Hittelman,Mien-Chie Hung,Dihua Yu

DOI: https://doi.org/10.1158/0008-5472.22379625.v1

2023-01-01

Abstract:Supplementary Tables 1-5 from 14-3-3ζ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival
Association of EZH2 Genotypes with Oral Cancer Risk.

Liang-Chun Shih,Chia-Wen Tsai,Tzu-Chieh Lin,Yun-Chi Wang,Jie-Long He,Che-Lun Hsu,Te-Chun Hsia,Fuu-Jen Tsai,Jai-Sing Yang,Yuan-Man Hsu,Da-Tian Bau,Wen-Shin Chang

DOI: https://doi.org/10.21873/invivo.13002

2022-01-01

Abstract:BACKGROUND/AIM:The over-expression of enhancer of zeste homolog 2 (EZH2) protein is found in oral cancer tissues. However, the genetic role of the enhancer of EZH2 in the etiology of oral cancer is unknown. The aim of this study was to evaluate the association of EZH2 genotypes with oral cancer risk among Taiwanese.MATERIALS AND METHODS:Three polymorphic variants of EZH2, rs887569 (C to T), rs41277434 (A to C), and rs3757441 (T to C), were analyzed regarding their association with oral cancer risk among 958 oral cancer patients and the same number of healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). In addition, the interaction of EZH2 rs887569, rs41277434, and rs3757441 genotypes with personal behaviors such as smoking, alcohol drinking, and betel quid chewing were also examined.RESULTS:The EZH2 genotypes rs887569, rs41277434, and rs3757441, were not significantly associated with oral cancer risk (p for trend=0.1735, 0.5658, and 0.4606, respectively). The analysis of allelic frequency distribution also supported the findings that the variant alleles at EZH2 rs887569, rs41277434, and rs3757441 may not serve as determinants of oral cancer risk (all p>0.05). There was no interaction between EZH2 rs887569, rs41277434, or rs3757441 genotypes with personal smoking, alcohol drinking or betel quid chewing behaviors.CONCLUSION:EZH2 genotypes cannot predict oral cancer risk in Taiwan.
Supplementary Table 2 from FGFR4 Promotes Stroma-Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer

Rui Liu,Jingyi Li,Ke Xie,Tao Zhang,Yunlong Lei,Yi Chen,Lu Zhang,Kai Huang,Kui Wang,Hong Wu,Min Wu,Edouard C. Nice,Canhua Huang,Yuquan Wei

DOI: https://doi.org/10.1158/0008-5472.22398243

2023-01-01

Abstract:PDF file, 71K, Clinico-pathologic parameters of colorectal cancer patients.
Supplementary Tables 1 and 2 from L-Plastin Promotes Gastric Cancer Growth and Metastasis in a <i>helicobacter Pylori Caga</i>-Erk-sp1–dependent Manner

Yong‐Sheng Teng,Wan‐Yan Chen,Zong‐Bao Yan,Yi-pin Lv,Yu-Gang Liu,Fangyuan Mao,Yongliang Zhao,Peng Li,Cheng Peng,Mubing Duan,Weisan Chen,Yu Wang,Ping Luo,Quanming Zou,Jun Chen,Yuan Zhuang

DOI: https://doi.org/10.1158/1541-7786.22527068.v1

2023-01-01

Abstract:Supplementary Table S1. The primers used for real-time PCR analysis Supplementary Table S2. ABPs obtained from Kyoto Encyclopedia of Genes and Genomes (KEGG) database

Supplementary Table 1 from EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia

Immunohistochemical Detection of Aurora A and ERK Pathway in Oral Leukoplakia and Oral Squamous Cell Carcinoma

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Abstract 1143: EZH2 Promotes Oral Squamous Cell Carcinoma Initiation and Progression Through Epigenetic Silencing of FHL1

Supplementary Table S3 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplemental Tables 1-4 from Notch1 Mutations Are Drivers of Oral Tumorigenesis

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Up-regulation of Enhancer of Zeste Homolog 2 is Associated Positively with Cyclin D1 Overexpression and Poor Clinical Outcome in Head and Neck Squamous Cell Carcinoma.

Supplementary Data from Methylation of &lt;i&gt;p16&lt;/i&gt; CpG Island Associated with Malignant Progression of Oral Epithelial Dysplasia: A Prospective Cohort Study

Supplementary Tables 1-2, Figure 1 from HOXA13 Promotes Cancer Cell Growth and Predicts Poor Survival of Patients with Esophageal Squamous Cell Carcinoma

Supplementary Tables from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth Via ADAM9–EGFR–AKT Signaling

Supplemental Figure 2 from Notch1 Mutations Are Drivers of Oral Tumorigenesis

Supplementary Tables 1-5 from 14-3-3ζ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival

Association of EZH2 Genotypes with Oral Cancer Risk.

Supplementary Table 2 from FGFR4 Promotes Stroma-Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer

Supplementary Tables 1 and 2 from L-Plastin Promotes Gastric Cancer Growth and Metastasis in a &lt;i&gt;helicobacter Pylori Caga&lt;/i&gt;-Erk-sp1–dependent Manner

Supplementary Data from Methylation of <i>p16</i> CpG Island Associated with Malignant Progression of Oral Epithelial Dysplasia: A Prospective Cohort Study

Supplementary Tables 1 and 2 from L-Plastin Promotes Gastric Cancer Growth and Metastasis in a <i>helicobacter Pylori Caga</i>-Erk-sp1–dependent Manner